Skip to content

Peretz Golding

3 papers in the library · 37 citations · publishing 2024-2026

Papers

Sort Most recent Most cited

Preclinical Comparison of DMT and 5-MeO-DMT Reveals Behavioral Dissociation, Distinct TrkB Activation and Differential Plasticity Profiles

bioRxiv (Cold Spring Harbor Laboratory) August 12, 2026 Orr Shahar, Alexander Botvinnik, Masha Chaykin et al. preprint

Abstract N, N-dimethyltryptamine (DMT) and 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) are structurally related tryptamine psychedelics with emerging therapeutic potential, yet their comparative acute pharmacology and longer-term neuroplastic effects remain incompletely defined. Here we show that DMT produces a bell-shaped dose–response curve in the mouse head-twitch response (HTR) assay,...

204. A NOVEL, NON-HALLUCINOGENIC PSYCHEDELIC FOR THE TREATMENT OF OCD AND TIC DISORDER

The International Journal of Neuropsychopharmacology August 1, 2025 Bernard Lerer, Peretz Golding, Michal Brownstien et al.

Abstract Background We have designed a novel psychedelic-derived compound (HBL20017) characterized by high functional efficacy at 5-HT2A, 5-HT1A, and 5-HT2C receptors. We assessed its hallucinogenic properties and its potential for OCD treatment on the marble burying test (MBT) and in mice homozygous for deletion of the Synapse Associated Protein 3 (SAPAP3) gene. These mice manifest severe,...

Effect of chemically synthesized psilocybin and psychedelic mushroom extract on molecular and metabolic profiles in mouse brain.

Molecular Psychiatry July 1, 2024 Orr Shahar, Alexander Botvinnik, Amit Shwartz et al. 37 citations

Psilocybin, a naturally occurring, tryptamine alkaloid prodrug, is currently being investigated for the treatment of a range of psychiatric disorders. Preclinical reports suggest that the biological effects of psilocybin-containing mushroom extract or "full spectrum" (psychedelic) mushroom extract (PME), may differ from those of chemically synthesized psilocybin (PSIL). We compared the effects...